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The signaling lipid sphingosine-1-phosphate (S1P) stabilizes the vasculature, directs lymphocyte egress from lymphoid organs, and shapes inflammatory responses. However, little is
known about how S1P distribution is controlled in vivo, and it is not clear how a ubiquitously made lipid functions as a signal that requires precise spatial and temporal control.
We have found that lipid phosphate phosphatase 3 (LPP3) enables efficient export of
mature T cells from the thymus into circulation, and several lines of evidence suggest that
LPP3 promotes exit by destroying thymic S1P. Although five additional S1P-degrading
enzymes are expressed in the thymus, they cannot compensate for the loss of LPP3. Moreover, conditional deletion of LPP3 in either epithelial cells or endothelial cells is sufficient
to inhibit egress. These results suggest that S1P generation and destruction are tightly
regulated and that LPP3 is essential to establish the balance.
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Susan.Schwab@med.nyu.edu
Abbreviations used: CD4SP,
CD4 single-positive; DN, double negative; DP, double positive; LPP3, lipid phosphate
phosphatase 3; MFI, mean fluorescence intensity; pIpC, polyinosinic:polycytidylic acid; S1P,
sphingosine-1-phosphate;
S1PR1, S1P receptor 1; SPP1,
S1P phosphatase 1.

The signaling lipid sphingosine-1-phosphate
(S1P) plays critical roles in mammalian biology.
Extracellular S1P binds five G protein–coupled
receptors, S1P receptors 1–5 (Hla, 2004), and
intracellular S1P binds an expanding set of proteins (Hait et al., 2009; Alvarez et al., 2010;
Puneet et al., 2010). The concentration of S1P
is high in circulatory fluids, and plasma S1P stabilizes junctions between vascular endothelial cells (Lee et al., 1999; Kono et al., 2008;
Camerer et al., 2009).The concentration of extracellular S1P is low in lymphoid tissues compared with blood and lymph, and this difference
directs lymphocyte egress from lymphoid organs
into circulation (Schwab and Cyster, 2007).
Although extracellular S1P in lymphoid organs,
and likely most tissues, is low in homeostasis,
S1P may increase upon inflammation. Elevated
S1P has been reported to promote angiogenesis
and to enhance proinflammatory responses of
innate and adaptive immune cells (Rivera et al.,
2008; Liu et al., 2010). Drugs targeting S1P signaling are in clinical trials as immune suppressants
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(Carroll, 2010). In fact, FTY720 has just been
approved by the United States Food and Drug
Administration for treatment of multiple sclerosis (Brinkmann et al., 2010). By blocking exit
from lymphoid organs, these drugs prevent activated T cells from trafficking to organs under
autoimmune attack. These drugs may also have
direct antiinflammatory effects.
Despite its importance, little is known about
how the distribution of S1P is controlled in
vivo. This question is particularly interesting
because it is difficult to understand how a ubiquitously made lipid functions as a signal that
requires precise spatial and temporal control.
To maintain low extracellular tissue S1P in homeostasis, several sources of S1P must be contained. First, all cells are thought to make S1P
intracellularly as an intermediate in membrane
© 2011 Bréart et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months
after the publication date (see http://www.rupress.org/terms). After six months
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sphingolipid metabolism (Hannun and Obeid, 2008); metabolic S1P must be destroyed before it accumulates in the
interstitial space. Second, plasma S1P must be excluded from
the tissue. S1P concentrations in plasma are in the micromolar
range, and although tissues are constantly bathed with transudated plasma to bring nutrients and remove waste, S1P in the
interstitial fluid of lymphoid organs has been estimated to be
sub-nanomolar (Schwab and Cyster, 2007). S1P’s abundance
suggests the possibility that levels could be changed rapidly in
response to physiological cues and the requirement that its
concentration be tightly regulated.
Many factors are undoubtedly required to maintain low
tissue S1P, but one key is likely how S1P is degraded. Strikingly, not one but six enzymes are known to destroy S1P in
vitro. These enzymes fall into two classes. The first consists of
S1P lyase, which cleaves S1P to 2-hexadecenal and phosphoethanolamine, and S1P phosphatases 1 and 2, which dephosphorylate S1P to sphingosine (Saba and Hla, 2004). These
three enzymes are thought to be highly specific for S1P and
reside predominantly in the endoplasmic reticulum. S1P lyase
is required to maintain low lymphoid organ S1P (Schwab et al.,
2005). Although the source of S1P destroyed by S1P lyase is
not known, it is likely to be S1P made in the course of sphingolipid metabolism; S1P lyase’s intracellular location positions
it well for this function. The second class of S1P-degrading
enzymes consists of three phosphatases: lipid phosphate phosphatases 1, 2, and 3 (Roberts et al., 1998; Brindley et al., 2000;
Pyne et al., 2004). These enzymes can dephosphorylate a
range of substrates, including S1P, ceramide-1-phosphate,
lysophosphatidic acid, and phosphatidic acid. The lipid phosphate phosphatases have been shown in many cell types to
localize to the plasma membrane with their active site facing
outside the cell, well positioned to degrade extracellular lipid
entering the tissues from the blood or secreted by tissue-resident
cells. The role of the lipid phosphate phosphatases in controlling tissue S1P is largely unknown.
In this paper, we asked what is the role of lipid phosphate
phosphatase 3 (LPP3; encoded by Ppap2b) in regulating extracellular S1P within lymphoid organs. We found that LPP3 is
essential to enable efficient export of mature T cells from the
thymus to the blood, and several lines of evidence suggest that
LPP3 promotes egress by maintaining low thymic S1P. Although
all six S1P-degrading enzymes are expressed in the thymus,
the loss of LPP3 alone in either epithelial cells or endothelial
cells is sufficient to delay exit.
RESULTS
LPP3 is required to keep thymic S1P low
Because LPP3 is essential in embryonic development (EscalanteAlcalde et al., 2003), we used Ppap2bf/f mice to study the function of LPP3 in lymphoid organs (Escalante-Alcalde et al.,
2007). We crossed in Cre recombinase driven by the interferon-inducible Mx1 promoter (Mx1-Cre; Kühn et al., 1995).
Pups were treated with polyinosinic:polycytidylic acid (pI-pC)
3–5 d after birth to activate the Mx1 promoter and Cre expression. Adults were analyzed at least 6 wk later. This induction


of Mx1-Cre mediates efficient deletion in a wide range of
tissues and lineages, including hematopoietic cells and a subset of endothelial cells (Pappu et al., 2007). For simplicity,
we refer to pI-pC–treated Ppap2bf/ Mx1Cre+ and Ppap2bf/f
Mx1Cre+ mice as LPP3 deficient. Littermate controls were
pI-pC treated at the same time as LPP3-deficient mice and
retained at least one intact copy of LPP3. To assess whether
LPP3 regulates thymic S1P, we examined three parameters
that are dependent on S1P signaling: the rate of exit of mature
T cells from the thymus, the level of surface CD69 on mature
thymocytes, and the level of surface S1P receptor 1 (S1PR1)
on mature thymocytes.
LPP3 deficiency impairs thymic egress
We first asked whether egress of mature T cells from the
thymus was impaired in LPP3-deficient mice. T cells must
express S1PR1 to exit lymphoid organs into circulatory fluids
(Allende et al., 2004; Matloubian et al., 2004; Weinreich and
Hogquist, 2008). Furthermore, disruption of the S1P gradient, either by removing circulatory S1P (Pappu et al., 2007)
or by raising lymphoid tissue S1P (Schwab et al., 2005), blocks
egress. We expected that if thymic S1P were elevated in the
absence of LPP3, exit would be slowed, resulting in an accumulation of mature T cells in the thymus.
We observed a 2.5-fold increase in the percentage of
mature CD4 single-positive (CD4SP) T cells (CD4+CD8
CD62LhiCD69lo) among total CD4SP (CD4+CD8) thymocytes in LPP3-deficient mice compared with littermate
controls (Fig. 1, A and B). There is also an increase in the
percentage of CD4SP T cells among total thymocytes. When
we calculated absolute numbers, we found a 4.5-fold increase
of mature CD4SP T cells in the thymus of LPP3-deficient
mice without any change in the number of immature CD4SP
precursors (Fig. 1 C).The absolute numbers are more variable
than the percentages, as the total size of the thymus varies
with many factors including age and stress. Nonetheless, in
each case the number of mature CD4SP was larger in the
LPP3-deficient mouse than its littermate control. We saw no
change in the number of double-negative (DN) T cells and a
30% reduction in the number of double-positive (DP) T cells in
the thymus of LPP3-deficient mice compared with littermate
controls (Fig. S1 A). As one might predict from a slowing of
thymic egress, we saw a moderate reduction in the number
of T cells in the periphery (Fig. S1 B). Mature CD8 singlepositive T cells similarly accumulate in the thymus of LPP3deficient mice (Fig. S1 C).
The accumulation of mature T cells suggests an egress
block but could also result from enhanced proliferation of
mature T cells. Developing T cells mature from the DN to the
DP to the SP stage. In WT mice, thymocytes proliferate
extensively as they transition from DN to DP and relatively
infrequently at the SP stage (Egerton et al., 1990). To assess the
possibility that mature SP T cells divide more frequently in
LPP3-deficient mice, we treated mice continuously with the
thymidine analogue BrdU in the drinking water to label proliferating cells. After 11 d of BrdU treatment, virtually all
LPP3 enables thymic egress | Bréart et al.
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Figure 1. LPP3 is required for efficient thymic egress.
LPP3-deficient mice (; Ppap2bf/Mx1Cre+ or Ppap2bf/f
Mx1Cre+, treated with pI-pC 3–5 d after birth) and littermate
controls (F; Ppap2bf/+Mx1Cre+, Ppap2b+/Mx1Cre+,
Ppap2bf/, Ppap2bf/f, Ppap2bf/+, or Ppap2b+/, treated with
pI-pC 3–5 d after birth at the same time as LPP3-deficient
mice) were analyzed at 6 wk or older. (A) Expression of CD4
and CD8 by total thymocytes (top) and expression of CD69
and CD62L by CD4SP (CD4+CD8) thymocytes (bottom) from
a representative LPP3-deficient mouse () and littermate
control (F). (B) Percentage of mature CD4SP thymocytes
(CD4+CD8CD62LhiCD69lo) among total CD4SP thymocytes.
(C) Total number of mature CD4SP thymocytes and immature CD4SP thymocytes (CD4+CD8CD62LloCD69hi). In B and
C, each point represents an individual mouse and bars show
the mean. Graphs are a compilation of 13 experiments with
a total of 21 mice per group. In all figures, p-values were
calculated using the two-tailed unpaired Student’s t test.
(D) LPP3-deficient mice and littermate controls were treated
with 0.8 mg/ml BrdU in the drinking water for 11 d. BrdU
incorporation by mature CD4SP thymocytes, as well as naive
blood CD4+ T cells, was measured by flow cytometry. Data
are representative of three pairs of mice analyzed in three
experiments. (E) GFP levels of mature CD4SP thymocytes
from a representative Rag2p-GFP+ LPP3-deficient () mouse,
mature CD4SP thymocytes from its Rag2p-GFP+ littermate
control (F), and naive (CD69LhiCD69lo) CD4+ T cells from the blood of the LPP3-deficient Rag2p-GFP+ mouse, measured by flow cytometry. Data are representative of four pairs of mice analyzed in two experiments. (F) Sulfo-NHS biotin was injected into the thymus of LPP3-deficient mice and littermate controls. 16 h later, biotin-labeled mature CD4SP T cells in the thymus and CD4+ T cells in the periphery (combined blood, spleen, mesenteric, inguinal,
axillary, and brachial LNs) were enumerated. The graph shows the ratio of the number of labeled cells in the periphery to the number of labeled cells remaining in the thymus. Each point represents an individual mouse and bars show the mean. The graph compiles data from seven LPP3-deficient mice and
four littermate controls analyzed in two experiments. Mature T cells in the thymus of LPP3-deficient and littermate controls were labeled with similar
efficiency (mean 57 and 62%, respectively).

mature CD4SP T cells in control mice were BrdU+ (Fig. 1 D).
In contrast, in LPP3-deficient mice a substantial number of
mature CD4SP T cells remained unlabeled (Fig. 1 D). The increased fraction of BrdU mature SP T cells is inconsistent
with enhanced proliferation of mature SP thymocytes in LPP3deficient mice. Instead, it is consistent with delayed egress; the
BrdU cells likely developed before the labeling period began
and remained in the thymus for an extended period. Mature
CD8SP T cells had a similar pattern (Fig. S1 D).
Although an accumulation of mature T cells in the absence
of proliferation is consistent with a failure to exit, it is also
possible that this could reflect enhanced reentry of peripheral
T cells into the thymus. To distinguish between these possibilities, we took advantage of Rag2p-GFP reporter mice (Yu
et al., 1999; Boursalian et al., 2004). In these mice, GFP transcription is driven by the Rag2 promoter. After RAG is turned
off at the DP stage, GFP protein levels decay with a half-life
of 56 h (McCaughtry et al., 2007). GFP acts as a clock, with
its abundance reflecting the amount of time that has passed
since positive selection. Analysis of LPP3-deficient Rag2pGFP+ mice and Rag2p-GFP+ littermate controls revealed that
mature CD4SP LPP3-deficient thymocytes have lower GFP
than mature CD4SP control thymocytes but higher GFP than
naive CD4 T cells circulating in the periphery (Fig. 1 E). Mature
CD8SP T cells behave similarly (Fig. S1 E). This pattern is
JEM Vol. 208, No. 6

consistent with prolonged thymic residence and delayed egress
but not with reentry of peripheral T cells.
Finally, we directly tested the efficiency of thymic egress
by injecting sulfo-NHS biotin into the thymus of LPP3deficient mice and littermate controls and tracking the
appearance of labeled cells in the periphery. To minimize
inflammation, we used ultrasound to guide the injection needle
(Blair-Handon et al., 2010). After 16 h, we found that the
ratio of labeled CD4+ T cells in the periphery (pooled blood,
spleen, and LNs) to labeled mature CD4SP T cells remaining
in the thymus was 0.2 in LPP3-deficient mice and 1.3 in controls (Fig. 1 F). Approximately twofold fewer labeled cells had
emigrated to the periphery in LPP3-deficient mice, whereas
threefold more labeled cells stayed in the thymus. These
results are again consistent with an exit defect.
LPP3 deficiency causes down-modulation of CD69
on mature T cells
Our second indication that LPP3 regulates thymic S1P was
the level of the activation marker CD69 on mature SP thymocytes. Mature SP T cells normally express intermediate levels
of CD69, as they have recently completed positive selection,
but S1P signaling causes rapid down-modulation of surface
CD69. This observation was first made in mice treated with
the S1P receptor agonist AAL-(R) (Rosen et al., 2003) and


reproduced in mice treated with the S1PR1-selective agonist
SEW2871 (Alfonso et al., 2006). CD69 and S1PR1 interact,
and S1PR1 mediates CD69 internalization in a pertussis toxin–
sensitive manner (Shiow et al., 2006). CD69 is down-modulated
on mature but not immature SP T cells. S1pr1 mRNA is
>10-fold more abundant in mature than in immature CD4SP
thymocytes (Matloubian et al., 2004), and surface S1PR1
protein is readily detectable on mature but not immature SP
T cells (Zachariah and Cyster, 2010). We expected that if S1P
were elevated in the thymus of LPP3-deficient mice, surface
CD69 on mature SP T cells would decrease.
We observed down-modulation of CD69 on the surface
of mature SP T cells in LPP3-deficient animals compared
with littermate controls (Fig. 1 A). To pool experiments, we
calculated the ratio of CD69 mean fluorescence intensity
(MFI) of littermate control mature CD4SP thymocytes/
CD69 MFI of LPP3-deficient mature CD4SP thymocytes.
This ratio was 3 (Fig. 2 A). The down-modulation of CD69
on mature T cells in LPP3-deficient mice is not simply secondary to a longer residence time, as it was also seen on the
recently mature GFPhi cells in LPP3-deficient Rag2p-GFP+
mice (Fig. 2 B).The decreased CD69 on mature T cells is also
not the result of a failure to up-regulate fully CD69 during
positive selection, as we saw no difference in the level of CD69
on immature CD4SP T cells from LPP3-deficient mice and
littermate controls (Figs. 1 A and 2 C).
LPP3 deficiency causes internalization of S1PR1
Our third test of whether LPP3 is required to maintain
low extracellular thymic S1P was the level of surface
S1PR1 on mature SP T cells. Mature SP T cells normally
express abundant S1PR1, enabling them to exit the thymus efficiently (Matloubian et al., 2004). S1PR1 is internalized upon binding S1P (Liu et al., 1999; Schwab et al.,
2005), and we expected that if LPP3-deficient mice had

elevated thymic S1P, surface S1PR1 on thymic T cells
would be reduced.
We found that the level of S1PR1 is two- to threefold
lower on the surface of mature SP thymocytes of LPP3-deficient
mice than littermate controls (Fig. 2 D). S1pr1 transcript is
comparable between LPP3-deficient and littermate control mice,
suggesting that the decrease is posttranscriptional (Fig. S2 A).
CCR7 surface protein also does not differ between LPP3deficient and littermate control mice, suggesting that the
decrease does not reflect a global down-modulation of G
protein–coupled receptors (Fig. S2 B).
Collectively, the egress block, CD69 down-modulation, and
reduction in surface S1PR1 strongly suggest that the S1Pdegrading enzyme LPP3 is required to maintain low thymic
S1P. Using mass spectrometry, we were unable to detect elevated S1P in whole thymic tissue of LPP3-deficient mice
(Fig. S2C), which is not surprising given the incomplete
down-modulation of S1PR1. The concentration of S1P in the
thymus of control animals is 0.5 pmol/mg wet weight, which
translates to 500 nM assuming that the density of the thymus
is the same as water (an underestimate).This is consistent with
previous measurements of S1P in the whole embryo (Mizugishi
et al., 2005). In contrast to the total level of S1P in the thymus,
10 nM of extracellular S1P is sufficient to decrease surface
S1PR1 on mature thymocytes to below our limit of detection
(Schwab et al., 2005).The S1P measured by mass spectrometry
of whole thymic tissue is largely inaccessible to S1P receptors,
consistent with S1P’s role as an intracellular metabolic intermediate. Against the variability of our measurements of S1P in
control thymus, we are unable to detect an increase in extracellular S1P that causes partial receptor internalization.
LPP3 is required in radiation-resistant cells
To determine which cell type requires LPP3 to maintain
low thymic S1P, we began by generating BM chimeras.

Figure 2. LPP3 deficiency causes downmodulation of CD69 and S1PR1. (A) The
ratio of CD69 MFI of mature CD4SP thymocytes from littermate controls (F)/CD69 MFI of
mature CD4SP thymocytes from LPP3deficient mice (). Each point represents one
pair of mice, and the bar represents the mean.
The graph compiles 13 experiments with a
total of 21 pairs of mice. (B) Dot plots (left)
show expression of GFP versus forward scatter (FSC) by mature CD4SP T cells from a representative Rag2p-GFP+ LPP3-deficient mouse
() and Rag2p-GFP+ littermate control (F),
and they indicate the GFPhi gate. The GFP MFI
within the GFPhi gate differs by <10% between littermate controls and LPP3-deficient
mice. The bar graph (right) shows the ratio of CD69 MFI of GFPhi mature CD4SP thymocytes from Rag2p-GFP+ littermate controls/CD69 MFI of GFPhi mature CD4SP thymocytes from Rag2p-GFP+ LPP3-deficient mice. Each point represents one pair of mice, and each bar represents the mean. The graph
compiles data from four pairs of mice analyzed in two experiments. (C) The ratio of CD69 MFI of immature CD4SP thymocytes from littermate controls
(F)/CD69 MFI of immature CD4SP thymocytes from LPP3-deficient mice (). Each point represents one pair of mice, and each bar represents the mean.
The graph compiles six experiments with a total of eight pairs of mice. (D) Surface S1PR1 levels on mature CD4SP thymocytes. The thin line shows staining with a control antibody. Data are representative of three pairs of mice analyzed in three experiments.
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Figure 3. LPP3 is required in radiation-resistant cells to maintain
low thymic S1P. CD45.2+ LPP3-deficient () mice and littermate controls
(F) were lethally irradiated and reconstituted with CD45.1+ WT BM. The
chimeras were analyzed 7–10 wk later. All analyses are gated on WT thymocytes (94–99% of total). (A) Percentage of mature CD4SP thymocytes
among total CD4SP thymocytes. (B) Total number of mature CD4SP thymocytes and immature CD4SP thymocytes. In A and B, each point represents an individual mouse and bars show the mean. Graphs are a
compilation of four experiments with a total of 10–11 mice per group.
(C) Expression of CD69 and CD62L on CD4SP thymocytes. (D) The ratio of
CD69 MFI of mature CD4SP thymocytes from littermate control chimeras/
CD69 MFI of mature CD4SP thymocytes from LPP3-deficient chimeras.
Each point represents one pair of mice, and the bar represents the mean.
The graph compiles 10 pairs of mice analyzed in four experiments.
(E) Surface S1PR1 expression on mature CD4SP thymocytes. The thin line
shows staining with a control antibody. Data are representative of three
pairs of mice analyzed in three experiments.

We observed no difference between lethally irradiated WT
mice reconstituted with LPP3-deficient BM and mice reconstituted with littermate control BM (Fig. S3, A–E). However,
when we compared lethally irradiated LPP3-deficient and
littermate control mice reconstituted with WT BM, we found
a striking difference. WT mature SP thymocytes in LPP3deficient animals have a fivefold accumulation (Fig. 3, A and B),
a decrease in CD69 (Fig. 3, C and D), and a two- to threefold
decrease in S1PR1 (Fig. 3 E). This suggests that LPP3 is required in radiation-resistant cells to maintain low thymic S1P.
It is interesting to note that this pattern contrasts with that of
S1P lyase, which is required in hematopoietic cells to maintain low lymphoid S1P (Schwab et al., 2005; lyase expression
by stromal cells is likely also important). Treatment of LPP3deficient mice with the S1P lyase inhibitor deoxypyridoxineHCl further increases thymic S1P (Fig. S3 F).
JEM Vol. 208, No. 6

LPP3 is expressed by multiple radiation-resistant cell types
To determine which radiation-resistant cell type must ex
press LPP3 to maintain low thymic S1P, we began by asking
which cells express Ppap2b mRNA using quantitative PCR
on sorted cells from WT mice. Consistent with the importance
of LPP3 on radiation-resistant cells, we found that Ppap2b
mRNA is enriched 100-fold in CD45 thymic stroma compared with T cells. However, there are no dramatic differences
in expression between EpCAM+ epithelial cells, CD31+ endothelial cells, and other CD45 stromal cells (Fig. 4 A). We
also asked whether any of these cell types differ in expression
of the other five S1P-degrading enzymes, suggesting that they
might be uniquely dependent on LPP3. We found that LPP1
(Ppap2a) and LPP2 (Ppap2c) have a similar pattern to LPP3
(Fig. 4 A) and that the S1P-specific enzymes S1P lyase (Spgl1),
S1P phosphatase 1 (SPP1; Sgpp1), and SPP2 (Sgpp2) are also
expressed by all subsets of radiation-resistant cells (Fig. 4 B).
Our next attempt to narrow down the cell type that must
express LPP3 was to ask whether Mx1-Cre deletes preferentially in any radiation-resistant cell types in the thymus. We
crossed mice expressing Mx1-Cre with an enhanced (E) YFP
reporter strain, R26R-EYFP, which has EYFP in the ubiquitously expressed Rosa26 locus preceded by a floxed transcriptional stop (Srinivas et al., 2001), treated the pups with pI-pC
at 3–5 d after birth, and analyzed the mice as adults. Analysis
of disaggregated thymocytes by flow cytometry revealed deletion in approximately two thirds of epithelial cells, one third
of endothelial cells, and 10% of other stroma, as well as >90%
of hematopoietic cells (Fig. 4 C). Because the strong YFP expression by lymphocytes obscured analysis of YFP expression
by radiation-resistant cells using confocal microscopy, we also
reconstituted lethally irradiated adults with WT BM. Analysis
of thymic sections from the chimeras confirmed that Mx1Cre deletes in multiple radiation-resistant cell types, including
epithelial cells and endothelial cells (Fig. 4 D).
Staining of frozen thymic sections with an antibody to
LPP3 revealed robust protein expression by medullary epithelial cells, which was largely absent in LPP3-deficient mice
(Fig. 4 E). LPP3 seemed to ring the endothelial wall of blood
vessels, consistent with results showing that LPP3 localizes to
the basolateral side of cultured MDCK cells (Jia et al., 2003).
This staining was less frequent in LPP3-deficient mice (Fig. 4 E).
LPP3 protein was also expressed by a range of other stromal
cells, likely including pericytes (Fig. S4).
LPP3 is required in both endothelial cells and epithelial cells
We then began a candidate approach to determine which cell
type must express LPP3. Because we observed high expression
of LPP3 by endothelial cells and partial deletion in endothelial cells by Mx1-Cre, and because endothelial cells sit at the
border of the high S1P environment of the blood and the
low S1P environment of the thymus, we considered the possibility that LPP3 was required in endothelial cells to maintain
low thymic S1P. To delete LPP3 in vascular endothelial cells,
we crossed Ppap2bf/f mice with mice carrying Cre recombinase driven by the Tie2 promoter (Kisanuki et al., 2001).


Figure 4. LPP3 is expressed by multiple radiation-resistant
cell types. (A and B) Abundance of mRNA transcripts encoding the indicated S1P degrading enzymes, expressed relative to
Hprt (hypoxanthine-guanine phosphoribosyltransferase) transcript, in sorted thymic populations, measured by quantitative
RT-PCR. Ppap2a, LPP1; Ppap2b, LPP3; Ppap2c, LPP2; Sgpp1,
SPP1; Sgpp2, SPP2; and Spgl1, S1P lyase. Endothelial cells were
defined as CD45CD31+, epithelial cells as CD45EpCAM+,
other stromal cells as CD45CD31EpCAM, and DP T cells as
CD4+CD8+ (none of the transcripts differ among DP, immature
CD4SP, or mature CD4SP T cells, not depicted). The point shows
the mean, and the vertical line shows the standard deviation.
Data compile three to six experiments with mice on a B6 or a
B6 × 129 mixed background (the results did not differ by
strain). Each experiment is a separate cell purification from
three to four pooled mice, RNA extraction, and quantitative
RT-PCR. (C) R26R-EYFP+ Mx1Cre+ mice were treated with pI-pC
3–5 d after birth and analyzed at least 6 wk later. YFP expression by disaggregated thymic cell populations was measured
by flow cytometry. CD45+ cells are primarily T cells, as they
were isolated by mechanical disruption. Each point represents
an individual mouse, and bars show the mean. The graph compiles two mice analyzed in two experiments. (D) R26R-EYFP+
Mx1Cre+ mice were treated with pI-pC 3–5 d after birth. Adults
were lethally irradiated and reconstituted with WT BM. The
resulting chimeras were analyzed 7–10 wk later. Frozen thymic
sections were stained for CD31 to mark endothelial cells or
EpCAM to mark epithelial cells and visualized by confocal
microscopy. Bars, 20 µm. The image is representative of two
mice analyzed in two experiments. (E) Frozen thymic sections
from LPP3-deficient mice and littermate controls were stained
for CD31 to mark endothelial cells, EpCAM to mark epithelial
cells, and LPP3 and were visualized by confocal microscopy.
Bars, 20 µm. The image is representative of two pairs of mice
analyzed in two experiments.

We had no live-born Ppap2bf/fTie2-Cre+ pups (unpublished
data), which was not surprising as Ppap2b/ embryos suffer
severe vascular defects (Escalante-Alcalde et al., 2003). To circumvent embryonic lethality, we used the inducible CreERT2
recombinase under the endothelial VE-Cadherin (Cdh5) promoter (Wang et al., 2010). We treated Ppap2bf/Cdh5(PAC)CreERT2+ mice, as well as littermate controls, with tamoxifen
to induce excision.
We saw a twofold accumulation of mature T cells in
Ppap2bf/Cdh5(PAC)-CreERT2+ mice compared with littermate controls, which is significant but smaller than in mice in
which deletion was mediated by Mx1-Cre (Fig. 5, A and B;
the cell number in Ppap2bf/Cdh5(PAC)-CreERT2+ mice is
less than in Ppap2bf/- or f/f Mx1Cre+ mice with P < 0.01). We
saw a moderate reduction in the number of T cells in the


periphery of these mice (Fig. S5 B). We observed
a decrease of surface CD69 on mature T cells, which
is, again, significant but less dramatic than in mice in
which deletion was mediated by Mx1-Cre (Fig. 5,
C and D; CD69 is higher in Ppap2bf/Cdh5(PAC)CreERT2+ than in Ppap2bf/ or f/f Mx1Cre+ mice
with P < 0.01). Finally, we observed at most a slight
down-modulation of S1PR1 on mature T cells (Fig. 5 E). We
suspect that down-modulation is difficult to detect as a result of the relatively mild phenotype and limited sensitivity of
our antibody.
To determine the pattern of deletion, we crossed mice
expressing Cdh5(PAC)-CreERT2 with the YFP reporter
strain. Confocal microscopy of thymic sections revealed specific deletion in endothelial cells (Fig. 5 F and Fig. S5 A),
which was confirmed by analysis of disaggregated thymic cells
by flow cytometry. We saw variable excision, ranging from 20
to 70%, whereas deletion in other cell types was undetectable
(Fig. 5 G). It is possible that the intermediate effect of LPP3
deletion within endothelial cells is a result of incomplete excision. It is also possible that the loss of LPP3 in endothelial
cells causes a very small increase in thymic S1P but that
LPP3 enables thymic egress | Bréart et al.
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Figure 5. LPP3 expression by endothelial
cells is required to maintain low thymic
S1P. Mice in which LPP3 was deleted by
VE-Cadherin-CreERT2 (VE-; Ppap2bf/
Cdh5(PAC)-CreERT2+, treated with tamoxifen
at 3–4 wk old) or littermate controls (VE-F;
Ppap2bf/+ Cdh5(PAC)-CreERT2+, Ppap2bf/+, or
Ppap2bf/-, treated with tamoxifen at 3–4 wk
old) were analyzed at least 4 wk after tamoxifen treatment. (A) Percentage of mature
CD4SP thymocytes among total CD4SP thymocytes. (B) Total number of mature CD4SP
thymocytes and immature CD4SP thymocytes.
In A and B, each point represents an individual mouse and bars show the mean.
Graphs are a compilation of 11 experiments
with a total of 14 mice per group. (C) Expression of CD69 and CD62L on CD4SP thymocytes. (D) The ratio of CD69 MFI of mature
CD4SP thymocytes from littermate controls/
CD69 MFI of mature CD4SP thymocytes from
VE- mice. Each point represents one pair of
mice, and the bar represents the mean. The
graph compiles 14 pairs of mice analyzed in
11 experiments. (E) Surface S1PR1 expression
on mature CD4SP thymocytes. The thin line
shows staining with a control antibody. We
saw slight down-modulation in two experiments and no detectable shift in a third.
(F) Frozen thymic sections from tamoxifentreated R26R-EYFP+Cdh5(PAC)-CreERT2+ mice
were stained for CD31 to mark endothelial cells and visualized by confocal microscopy. Bars, 100 µm. The image is representative of two mice analyzed in
two experiments. (G) YFP expression by disaggregated thymic cell populations from tamoxifen-treated R26R-EYFP+Cdh5(PAC)-CreERT2+ mice was measured by flow cytometry. CD45+ cells are primarily T cells, as they were isolated by mechanical disruption. Each point represents an individual mouse, and
bars show the mean. The graph compiles three mice analyzed in three experiments.

the elevated S1P is precisely where T cells most need a
sharp gradient to egress as they cross the blood vessel wall
into circulation.
Because we also observed high expression of LPP3 by
thymic epithelial cells and efficient deletion in thymic epithelial cells by Mx1-Cre, we considered the possibility that
LPP3 was required in these cells. To delete LPP3 in epithelial
cells, we used the Cre recombinase under the Keratin 14
promoter (Dassule et al., 2000). We bred Ppap2bf/Krt14-Cre+
mice. Littermate controls were Ppap2bf/+Krt14Cre+, Ppap2bf/+,
or Ppap2bf/.
Mature T cells in the thymus of Ppap2bf/Krt14-Cre+ mice
have a 3.5-fold accumulation (Fig. 6, A and B), accompanied
by a small reduction of T cells in the periphery (Fig. S6 B).
Mature T cells in the thymus of Ppap2bf/Krt14-Cre+ mice
also display down-modulation of CD69 (Fig. 6, C and D) and
a twofold decrease in S1PR1 compared with littermate controls (Fig. 6 E).
To determine the pattern of deletion, we crossed mice
expressing Keratin 14-Cre with the YFP reporter strain. In both
the LPP3 and YFP reporter crosses, Cre recombinase was
carried only by the father to avoid potential widespread deletion
as a result of expression in the oocyte (Hafner et al., 2004).
JEM Vol. 208, No. 6

Confocal microscopy of thymic sections revealed deletion
primarily in medullary epithelial cells (Fig. 6 F, Fig. S6 A).
This pattern was also seen in analysis of disaggregated thymic cells by flow cytometry. We observed excision within
75% of EpCAM+ cells (Fig. 6 G). We have confirmed a
requirement for LPP3 in epithelial cells using Ppap2bf/
Foxn1-Cre+ mice (Fig. S6, C and D); FoxN1-Cre deletes
specifically and universally in thymic epithelial cells (Gordon
et al., 2007).
DISCUSSION
We found that LPP3 is essential to enable efficient thymic
egress, and several lines of evidence suggest that LPP3 promotes exit by maintaining low thymic S1P. In the absence of
biochemical evidence of increased S1P, uncertainty remains
in the interpretation of our results; measurements of total thymic S1P by mass spectrometry are uninformative because the
background of intracellular S1P (500 nM), combined with
measurement variability, is too high to detect an increase in
extracellular S1P predicted to cause partial S1PR1 downmodulation (<10 nM or 2% of total). Nonetheless, because
S1P is the only LPP3 substrate that has been implicated in
egress, CD69 down-modulation, or S1PR1 internalization,


the simplest interpretation of our data is that LPP3 is functioning to limit thymic S1P.
This is the first time to our knowledge that a phosphatase has been implicated in lymphoid organ S1P regulation
in vivo. The Drosophila melanogaster homologues of LPP3,
wunen and wunen2, are required to guide germ cell migration in the developing embryo. Germ cells and the surrounding tissue compete for hydrolysis of a lipid phosphate,
although the identity of this lipid is unknown (Renault and
Lehmann, 2006). Ppap2b/ mice die at or before embryonic day 10.5 with failure to form a chorioallantoic placenta
and yolk sac vasculature (Escalante-Alcalde et al., 2003). It is
not known whether this phenotype is the result of an imbalance in phospholipids and, if so, which phospholipid, or
whether it is the result of a phosphatase-independent function of LPP3 (Humtsoe et al., 2003). Ppap2bf/fNestin-Cre+
mice have increased S1P in the cerebellum (López-Juárez
et al., 2011). LPP3 is needed on both endothelial and epithelial cells, revealing a novel role of epithelial cells in enabling
thymic egress.
We further found that although LPP1 and LPP2 have a
similar expression pattern to LPP3, and S1P lyase and SPP1
are widely expressed in the thymus, they cannot compensate
for the loss of LPP3. Moreover, deletion of LPP3 in either
epithelial cells or endothelial cells is sufficient to cause an
increase in thymic S1P and an egress block. These observations suggest that S1P generation and destruction are finely
balanced. Little is known about LPP3 regulation, although


Figure 6. LPP3 expression by epithelial cells is
required to maintain low thymic S1P. Mice in
which LPP3 was deleted by Keratin14-Cre (TEC-;
Ppap2bf/Krt14Cre+) or littermate controls (TEC-F;
Ppap2bf/+Krt14Cre+, Ppap2bf/+, or Ppap2bf/) were
analyzed at 6 wk or older. (A) Percentage of mature
CD4SP thymocytes among total CD4SP thymocytes.
(B) Total number of mature CD4SP thymocytes and
immature CD4SP thymocytes. In A and B, each point
represents an individual mouse and bars show the
mean. Graphs compile 11 experiments with a total of
13 mice per group. (C) Expression of CD69 and
CD62L on CD4SP thymocytes. (D) The ratio of CD69
MFI of mature CD4SP thymocytes from littermate
controls/CD69 MFI of mature CD4SP thymocytes
from TEC- mice. Each point represents one pair of
mice and the bar represents the mean. The graph
compiles 13 pairs of mice analyzed in 11 experiments. (E) Surface S1PR1 expression on mature
CD4SP thymocytes. Thin line shows staining with a
control antibody. Data are representative of three
pairs of mice analyzed in three experiments. (F) Frozen thymic sections from R26R-EYFP+Krt14Cre+ mice
were stained for EpCAM to mark epithelial cells and
CD8 to distinguish the cortex from the medulla and
visualized by confocal microscopy. Bar, 100 µm.
Image is representative of two mice in two experiments. (G) YFP expression by disaggregated thymic
cell populations from R26R-EYFP+Krt14Cre+ mice
was measured by flow cytometry. CD45+ cells are
primarily T cells, as they were isolated by mechanical
disruption. Each point represents an individual
mouse and bars show the mean. The graph compiles
two mice analyzed in two experiments.

LPP3 expression by endothelial cell
lines is increased upon
exposure to stimuli including VEGF and TNF (Humtsoe et al.,
2003; Wary and Humtsoe, 2005; Senda et al., 2009), and
LPP3 expression by epithelial lines is increased upon exposure to stimuli including EGF (Kai et al., 1997; Humtsoe
et al., 2003). We propose that S1P levels could be rapidly
increased in response to physiological signals, not only by
increasing phosphorylation of sphingosine but also simply by
inhibiting degradation. This may be one reason that a ubiquitous lipid evolved to be a signaling molecule.
One question raised by these findings is what is the normal spatial distribution of S1P within the thymus and how is
it altered in the absence of LPP3? On average, extracellular
S1P is lower in the thymus than in circulation (Schwab and
Cyster, 2007), but whether there are local variations remains
unknown. For example, whether a gradient of S1P guides
T cells toward egress structures or whether T cells encounter
S1P only as they probe the blood vessels is an open question.
We hypothesize that in the absence of LPP3 in epithelial cells,
which form a network throughout the thymus, S1P increases
widely in the tissue, masking local S1P gradients and desensitizing T cells to remaining egress cues. In the absence of LPP3
in endothelial cells, S1P may increase only proximal to blood
vessels. Although the loss of LPP3 in endothelial cells has a
LPP3 enables thymic egress | Bréart et al.

Ar ticle

minimal effect on average T cell S1PR1, it may desensitize
T cells to S1P just where they most need a sharp gradient to
cross into circulation. LPP3 is also expressed by other stromal
cells, likely including pericytes. Whether S1P is regulated differently in the thymic parenchyma, at the border with blood,
and in the perivascular space warrants further investigation.
A second, related, question raised by these findings is what
is the source of S1P that LPP3 destroys? LPP3 may be responsible for destroying excess S1P made intracellularly during
membrane sphingolipid metabolism and secreted at some
rate. LPP3 may also prevent plasma S1P from entering tissues.
Vascular endothelial cells sit at the boundary of the high S1P
environment of the blood and the low S1P environment of
the tissue, and endothelial LPP3 may prevent S1P from crossing the blood vessel wall. Hematopoietic cells, particularly
erythrocytes, are the major source of plasma S1P, but endothelial cells themselves may also contribute (Pappu et al., 2007;
Hla et al., 2008; Venkataraman et al., 2008). Blood vessel endothelial cells efficiently secrete S1P in culture (Venkataraman
et al., 2008), and lymphatic endothelial cells are the main
source of lymph S1P (Pham et al., 2010). Intriguingly, LPP3
has been shown to localize to the basolateral side of cultured
MDCK cells (Jia et al., 2003), and our LPP3 antibody stain
seems to ring blood vessels. The subcellular organization of
S1P metabolic enzymes may enable vascular endothelial cells
to play a dual role in S1P generation and destruction.Thymic
vessels are unique in that they have a double-walled structure
with vascular endothelial cells surrounded by epithelial cells
(Ushiki, 1986; Kato, 1997; Ushiki and Takeda, 1997; Mori
et al., 2007), so a requirement for LPP3 in epithelial cells is
also consistent with a role in destroying plasma S1P.
Although our original hypothesis was that LPP3 is destroying metabolic or plasma S1P, it is also possible that LPP3 is responsible for preventing the spread of S1P made and secreted
for a highly localized signaling. Like vascular endothelial cells,
epithelial cells express high levels of the S1P generating enzyme sphingosine kinase 1 (unpublished data). A role for S1P
production by thymic epithelial cells has not been shown, although many are plausible. Epithelial cell S1P secretion may
facilitate T cell egress, leading them across the first basement
membrane of the double-walled vessels.This would be analogous to the role of pericytes, which sit in the perivascular
space and whose S1P secretion promotes exit (Zachariah and
Cyster, 2010). Epithelial cell S1P may affect T cell motility or
shape T cell maturation; T cell S1PR1 has been shown to inhibit development of regulatory T cells (Liu et al., 2009), but
the source of S1P within the thymus has not been identified.
Finally, it is tempting to speculate that S1P may play a more
general role in epithelial cell junctions, analogous to its role in
endothelial barrier function. In this regard, it is interesting to
note that LPP3 was first cloned in an attempt to identify genes
required for intestinal epithelial cell differentiation (Barilà
et al., 1996). Currently there are no techniques to measure
changes in extracellular S1P in nonlymphoid tissues, but
LPP3 may play a role in regulating not only thymic S1P but
also S1P in heavily epithelial tissues, such as the lung, small
JEM Vol. 208, No. 6

intestine, and skin and may be an attractive target to manipulate S1P selectively in these organs. The observation that S1P
levels are very tightly regulated offers the hope that highly
specific drugs can be developed to manipulate S1P signaling,
lymphocyte trafficking, and inflammation.
MATERIALS AND METHODS
Mice. Ppap2bf/f (Escalante-Alcalde et al., 2007), R26R-EYFP (Srinivas et al.,
2001), Rag2p-GFP (Yu et al., 1999), Mx1-Cre (Kühn et al., 1995), Keratin
14-Cre (Dassule et al., 2000), FoxN1-Cre (Gordon et al., 2007), Tie2-Cre
(Kisanuki et al., 2001), and Cdh5(PAC)-CreERT2 (Wang et al., 2010) mice
have been previously described. CD45.2+ B6 and CD45.1+ congenic B6
mice were obtained from the National Cancer Institute.
To induce deletion by Mx1-Cre, 3–5-d-old mice received a single intraperitoneal injection with 50–100 µl pI-pC (Midland Scientific) at a concentration of 10 mg/ml in sterile PBS. To induce deletion by VE-Cadherin
CreERT2, 3–4-wk-old mice received three intraperitoneal injections on
three consecutive days with 50 µl tamoxifen (Sigma Aldrich) at a concentration of 20 mg/ml in maize oil.
Mice were housed in specific pathogen-free conditions at the Skirball
Institute animal facility. All animal experiments were performed in accordance with protocols approved by the New York University Institutional
Animal Care and Use Committee.
BM chimeras, BrdU labeling, intrathymic injection, and deoxypyridoxine treatment. For BM chimeras, recipients were lethally irradiated by
two 6.5 Gray doses of  irradiation from a cesium source separated by 3 h
and received 2–10 × 106 BM cells by intravenous injection. Chimeras were
analyzed at least 7 wk after transplantation. For BrdU labeling, 0.8 mg/ml of
BrdU (Sigma-Aldrich) was added to the drinking water and changed daily.
For intrathymic injection, mice were anesthetized with 4% isoflurane in
medical air and maintained under anesthesia using a nose cone with 1.5%
isoflurane in medical air. Hair was removed from the thorax using depilatory
cream, and animals were placed on a heat pad for the injection.Thymus visualization was performed in real time using a 30-MHz 707B ultrasound probe
(VisualSonics). The injection needle (Hamilton syringe with 30-gauge needle) was mounted on a 3D micromanipulator and the tip of the needle placed
in the imaging plane. 20 µl (10 µl in each lobe) sulfo-NHS biotin (Thermo
Fisher Scientific) at a concentration of 5 mg/ml in PBS was injected. For
4-deoxypyridoxine-HCl (DOP) treatment, 30 mg/liter DOP (Sigma-Aldrich)
and 10 g/liter sucrose (to overcome taste aversion) were added to the drinking water. Control mice received drinking water with 10 g/liter sucrose.
Cell preparation. Lymphocytes were isolated by mechanical disruption and
filtration through a 70-µm cell strainer and enumerated with a cell counter
(Z1 Particle Counter; Beckman Coulter) set to detect nuclei between 3.5 and
7 µm. Thymic stromal cells were isolated as previously described (Gray et al.,
2002). In brief, the thymus was diced into small pieces and rotated for 30 min
at 4°C in RPMI 1640 supplemented with 10 mM Hepes (RPMI/H).The supernatant containing lymphocytes was removed, the remaining fragments were
briefly agitated in ice cold RPMI/H, the supernatant containing lymphocytes
was removed, the fragments were briefly agitated once more in ice-cold
RPMI/H, and the supernatant containing lymphocytes was removed. The remaining fragments were subjected to three successive digestions for 15 min at
37°C in RPMI/H containing Blendzyme III (Roche) at 0.14 U/ml and DNase
I at 1 mg/ml. In the middle and at the end of the first digestion, the fragments
were disaggregated with a Pasteur pipette and the supernatant was discarded.
In the middle and at the end of the second digestion, the fragments were dis
aggregated with a 22-gauge needle. In the middle and at the end of the third
digestion, the fragments were disaggregated with a 26-gauge needle. The
supernatants from the final two digestions and remaining fragments were
pooled and incubated for 10 min on ice in PBS 1% FBS 5 mM EDTA to yield
a mixture enriched in stromal cells. Cells were stained and analyzed using a
FACSCalibur (BD) or LSRII (BD) or sorted using a MoFlo (Beckman Coulter) or FACSAria (BD). Data were analyzed using FlowJo (v. 8.8.1; Tree Star).


Quantitative RT-PCR. Total RNA was extracted from sorted cell populations using TRIZOL (Invitrogen) according to the manufacturer’s instructions. Before RT, RNA was treated with DNase I (Invitrogen). The RNA
was converted to cDNA with the Superscript III First Strand Synthesis System (Invitrogen) or the USB First-Strand cDNA Synthesis kit (Affymetrix)
according to the manufacturer’s instructions, using a mix of oligo dT and
random hexamers as primers. Real-time quantitative PCR was performed
on an iCycler using iQ SYBR Green Supermix (Bio-Rad Laboratories) according to the manufacturer’s instructions. To control for DNA contamination, primers were designed to span a large intron when possible, and a
reaction without reverse transcription was performed in parallel for each
sample/primer pair. To control for nonspecific amplification, the size of the
reaction products was analyzed by agarose gel electrophoresis. All primer pairs
were tested for linear amplification over two orders of magnitude. Primers used were the following: Hprt sense, 5-AGGTTGCAAGCTTGCTGGT-3; Hprt antisense, 5-TGAAGTACTCATTATAGTCAAGGGCA-3;
S1pr1 sense, 5-AGACCCAGAGTCCTG-3; S1pr1 antisense, 5-GCGA
GCAATCCAATG-3; Ppap2b sense, 5-GGTGGCCTGCTGCATAGTGTT-3; Ppap2b antisense, 5-TCCTGTCGATGATGTCCACGGG-3;
Ppap2a sense, 5-CATACTGGGGCTTGGCTT-3; Ppap2a antisense,
5-TCCGACGGCTTTGTAAAT-3; Ppap2c sense, 5-CCGGCTCTGCTGGAAGTGGG-3; Ppap2c antisense, 5-GCGGACCGTGAGGCAGGC-3;
Sgpp1 sense, 5-GGCGCATATTTGTAAGTTTGG-3; Sgpp1 antisense,
5-TTCTATCCTGGATGTCATTGCT-3; Sgpp2 sense, 5-TGTCTCAGCAGACTCTACAC-3; Sgpp2 antisense, 5-GAGTCCAGGGAATCGATGAG-3; Spgl1 sense, 5-TATTGCACCAAATATGAGCC-3; and Spgl1
antisense, 5-CTGTTGTTCGATCTTACGTC-3.
Antibodies. S1PR1-specific antibody and control were previously described (Lo et al., 2005). Some stainings were done with a second batch of
antiserum made in the same way and tested for specificity. In this case, a
polyclonal rabbit anti-GST antibody (Bethyl Laboratories, Inc.) was used as
a control. LPP3-specific antibody and staining technique were previously
described (López-Juárez et al., 2011).
Fluorochrome- or biotin-conjugated anti-CCR7 (clone 4B12), CD4
(clone RMA4-5 or GK1.5), CD8 (clone 53–6.7), CD19 (clone 6D5), CD31
(clone MEC13.3 for immunohistology, clone 390 for flow cytometry), CD44
(clone IM7), CD45 (clone 30F11), CD45.1 (clone A20), CD45.2 (clone
104), CD62L (clone MEL14), CD69 (clone H1.2F3), CXCR4 (clone 2B11),
EpCAM (clone G8.8), NK1.1 (clone PK136), CD25 (clone PC61), and
TCR- (clone GL3) were purchased from BioLegend, eBioscience, or BD.
Biotin-conjugated polyclonal anti–PDGFR- was purchased from R&D
Systems. Intracellular staining for BrdU was done using the BD FITC BrdU
Flow kit according to the manufacturer’s instructions.
Flow cytometry and confocal imaging. Flow cytometry was done using
standard conditions. All staining was performed on ice, except for CCR7
staining which was at 37°C. Staining for S1PR1 was done with 0.05% sodium azide in all buffers.
Confocal imaging was done using standard conditions. In brief, the thymus was excised, fixed overnight at 4°C in periodate-lysine-paraformaldehyde medium (PLP; 0.05 M phosphate buffer, pH 7.4, 0.1 M L-Lysine, 10 mg/ml
paraformaldehyde, and 2 mg/ml NaIO4) and progressively dehydrated at 4°C
in sucrose (10, 20, and 30% in PBS). Tissues were snap frozen in OCT compound (Tissue-Tek; Sakura). 10-µm-thick tissue sections were rehydrated
(rehydration and staining buffer was PBS with 4% mouse serum, 4% rat serum, 1% Triton X-100, and 0.1 M Tris), stained, and imaged using a confocal
microscope (LSM510; Carl Zeiss) with a 40× oil immersion objective.
Images were processed using ImageJ software (version 1.41; National Institutes
of Health).
Mass spectrometry. Before taking thymus, mice were perfused with 10 ml
PBS. Samples were snap frozen in liquid nitrogen and stored at 80°C. Lipids
were purified and mass spectrometry was performed as previously described
(López-Juárez et al., 2011).
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Online supplemental material. Fig. S1 shows the effect of LPP3 deletion
on the numbers of DN and DP T cells in the thymus, that LPP3 deletion is
associated with reduced numbers of CD4 T cells in LNs and spleen, and that
LPP3 deletion inhibits egress of mature CD8 T cells from the thymus. Fig. S2
shows that LPP3 deletion does not detectably alter S1pr1 transcript in mature
thymocytes or surface CCR7 expression on mature thymocytes, and that an
increase in total thymic S1P is not detectable by mass spectrometry. Fig. S3
shows that chimeras generated with LPP3-deficient BM do not have elevated
thymic S1P and that inhibition of S1P lyase further increases thymic S1P in
LPP3-deficient mice. Fig. S4 shows expression of LPP3 and the pericyte
marker PDGFR- by confocal microscopy. Fig. S5 shows specificity of deletion by Cdh5(PAC)-CreERT2 and a reduction in the number of T cells in the
periphery of Ppap2bf/Cdh5(PAC)-CreERT2+ mice. Fig. S6 shows specificity
of deletion by Krt14-Cre, a reduction in the number of T cells in the periphery of Ppap2bf/Krt14-Cre+ mice, and an accumulation of mature T cells
in the thymus of Ppap2bf/Foxn1Cre+ mice. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20102551/DC1.
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